Survival, Neurocognitive Function and Health-Related Quality of life outcomes after (R-)MBVP for PCNSL: Final Results of the HOVON 105 / ALLG NHL 24 Study.
Jacoline E C BrombergSamar IssaBronno van der HoltMatthijs van der MeulenLinda DirvenMonique C MinnemaTatjana SeuteMarc DurianGavin CullMarjolein W M van der PoelWendy Bernadina Catharina StevensJosee M ZijlstraDieta BrandsmaMarcel NijlandKylie D MasonAart BeekerMartine C J Abrahamse-TestrooteMartin J Van Den BentDaphne de JongJeanette K DoorduijnPublished in: Neuro-oncology (2023)
Long-term follow-up confirms lack of added value of rituximab in addition to MBVP and HD-cytarabine for PCNSL.